Panacea Biotec Limited

NSE:PANACEABIO.NS

513.65 (INR) • At close May 12, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2025 Q32025 Q22025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 1,634.91,473.51,157.21,364.61,5051,430.21,291.91,258.991,1521,051.21,1071,387.231,558.82,321.71,324.51,611.091,417.61,820.21,327.61,184.861,677.41,251.81,257.81,223.461,103.81,203.3992.8
Cost of Revenue 625.5431.9879.5969.91,140.8581.9548.6574.8477.8364.51,109.51,069.07465.91,038.8426.3588.81425.1638394.4395.55522.8368.9280.71,093.59253.4435.4244.7
Gross Profit 1,009.41,041.6277.7394.7364.2848.3743.3684.19674.2686.7-2.5318.161,092.91,282.9898.21,022.28992.51,182.2933.2789.311,154.6882.9977.1129.87850.4767.9748.1
Gross Profit Ratio 0.6170.7070.240.2890.2420.5930.5750.5430.5850.653-0.0020.2290.7010.5530.6780.6350.70.6490.7030.6660.6880.7050.7770.1060.770.6380.754
Reseach & Development Expenses 0000000328.40000000390.170000000255.83000
General & Administrative Expenses 000418.23000247.49000471.63000472.5000396.65000393.75000
Selling & Marketing Expenses 000113.04000218.21000220.05000183.74000209.78000136.44000
SG&A 00504.9543.2456.8508.70465.7440.40-2.5691.68000640.7000606.431,154.600530.19000
Other Expenses 1,019.61,058.4000339.6743.30139.4686.7001,079.81,282.9898.20992.51,182.2933.2-108.430882.9977.1129.85850.4767.9748.1
Operating Expenses 1,019.61,058.4504.9543.2456.8848.3743.3886.57595.1686.7-2.5687.791,079.81,282.9898.2783.26992.51,182.2933.2611.521,154.6882.9977.1385.68850.4767.9748.1
Operating Income -10.2-16.8-227.2-148.5-92.6-128.7383.6-99.74354-137.3-323.3-369.6313.1-48.8-126.1-49.638.4266.3112.1210261.1-170.7120.2-255.81-263.9-234352.2
Operating Income Ratio -0.006-0.011-0.196-0.109-0.062-0.090.297-0.0790.307-0.131-0.292-0.2660.008-0.021-0.095-0.0310.0270.1460.0840.1770.156-0.1360.096-0.209-0.239-0.1940.355
Total Other Income Expenses Net 5464.456.7127.376.150.9-253.3281.89-129.6370.4-188.316,452.23-504.7-481.3-446.6-476.96-438.5-454.4-439.8-802.4-439.4-534-3572,128.46174.2-751.1-663.9
Income Before Tax 43.847.6-170.5-21.2-16.5-77.8130.3182.15224.4233.1-511.616,082.6-491.6-530.1-572.7-526.56-400.1-188.1-327.7-592.4-178.3-704.7-236.81,872.65-89.7-985.1-311.7
Income Before Tax Ratio 0.0270.032-0.147-0.016-0.011-0.0540.1010.1450.1950.222-0.46211.593-0.315-0.228-0.432-0.327-0.282-0.103-0.247-0.5-0.106-0.563-0.1881.531-0.081-0.819-0.314
Income Tax Expense -0.60.5-11.7-1.35.55.120.5308.930.776.149.83,707.850.400.814.870.40.93.491.523.123.528.325.9749-24.526.6
Net Income 45.248-158-16.63-22.8-82.9109.8-121.67193.7157-561.412,374.45-492-530.1-573.5-541.86-400.5-193.3-341.3-696.77-213.2-750-282.71,859.27-159.4-970-352.6
Net Income Ratio 0.0280.033-0.137-0.012-0.015-0.0580.085-0.0970.1680.149-0.5078.92-0.316-0.228-0.433-0.336-0.283-0.106-0.257-0.588-0.127-0.599-0.2251.52-0.144-0.806-0.355
EPS 0.740.77-2.59-0.23-0.37-1.351.79-2.073.162.56-9.17202.03-8.03-8.65-9.36-8.85-6.54-3.16-5.58-11.38-3.48-12.25-4.6230.39-2.6-15.83-5.75
EPS Diluted 0.740.77-2.59-0.23-0.37-1.351.79-2.073.162.56-9.17202.02-8.03-8.65-9.36-8.85-6.54-3.16-5.58-11.38-3.48-12.25-4.6230.39-2.6-15.83-5.75
EBITDA 143.5144.2-74.575.183.124.4235.1287.7330.7343.8-398.616,500.7135.280.516.851.78170.4400.8237.3-48.9401.4-179.1284.8-663.8255.7-556.479.2
EBITDA Ratio 0.0880.098-0.0640.0550.0550.0170.1820.2290.2870.327-0.3611.8950.0870.0350.0130.0320.120.220.179-0.0410.239-0.1430.226-0.5430.232-0.4620.08